PHASE 1/2A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Platinum Resistant Epithelial Ovarian CancerAdvanced Or Metastatic Sclc
-
Age: Between 18 - 100 Years
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Diagnosis of locally advanced/unresectable or metastatic (stage IV) breast cancer, Small Cell Lung Cancer and/or select gynecologic malignancies including ovarian cancer.
- ECOG PS 0 or 1.
You may not be eligible for this study if the following are true:
-
- Participants with known symptomatic brain metastases requiring steroids.
- Participants with any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.
- Major surgery within 3 weeks prior to study entry and radiation therapy within 3 weeks prior to study entry.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.